Download this Paper Open PDF in Browser

Reassessing Safety for Nanotechnology Combination Products: What Do 'Biosimilars' Add to Regulatory Challenges for the FDA?

Jordan Paradise, Reassessing Safety for Nanotechnology Combination Products: What Do Biosimilars Add to Regulatory Challenges for the FDA?, 56 St. Louis U. L. J. 465 (2012).

Saint Louis U. Legal Studies Research Paper

56 Pages Posted: 29 May 2011 Last revised: 9 Jan 2014

Jordan Paradise

Loyola University Chicago School of Law

Date Written: June 28, 2011

Abstract

Amidst sweeping changes to the United States health care system ushered in by the Patient Protection and Affordable Care Act (ACA), the Food and Drug Administration continues to struggle to apply emerging technological innovations to often centuries-old product categorizations. The ACA’s introduction of a “biosimilar” pathway to market for biological products, modeled on abbreviated pathways to market for drugs and medical devices, further complicates the assessment of “safety” and measures of equivalence and similarly that allow products to hit the market faster. One area where this is particularly acute is that of nanobiotechnology, which has enabled a set of products that drift uncomfortably at the interface of drugs, medical devices, and biologics, blending unique and novel biological properties at the nanoscale that integrate chemical, mechanical and biological aspects into a wide range of consumer medical and health care products.

This article will argue that the creation of the biosimilar pathway will prove to be the straw that breaks the camel’s back unless the FDA develops new dynamic models to properly assess and regulate nanomedical combination products. This article will examine the existing frameworks of FDA oversight for medical and health care products, highlight nanotechnology (and nanobiotechnology and nanomedicine) specifically as an area where products are currently straddling traditional boundaries between FDA product categories, discuss recent FDA initiatives and agency procedures regarding nanotechnology, and will suggest an approach for the FDA to respond to nanobiotechnology, including more effective federal coordination; reorganization of the FDA either through Congressional action or Commissioner action in order to properly classify, assess, monitor, and regulate emerging nanomedical technologies and products; and changes to FDA policy regarding data requirements and post-market reporting from industry to address concerns about the scope of “safety” in the context of nanomedical products.

Keywords: nanotechnology, Food and Drug Administration, drugs, devices, biologics, health care reform

Suggested Citation

Paradise, Jordan, Reassessing Safety for Nanotechnology Combination Products: What Do 'Biosimilars' Add to Regulatory Challenges for the FDA? (June 28, 2011). Jordan Paradise, Reassessing Safety for Nanotechnology Combination Products: What Do Biosimilars Add to Regulatory Challenges for the FDA?, 56 St. Louis U. L. J. 465 (2012).; Saint Louis U. Legal Studies Research Paper . Available at SSRN: https://ssrn.com/abstract=1852465

Jordan K. Paradise (Contact Author)

Loyola University Chicago School of Law ( email )

25 E. Pearson
Chicago, IL 60611
United States

Paper statistics

Downloads
108
Rank
212,778
Abstract Views
808